DBVT insider trading
HealthcareDBV Technologies S.A.: insider trade history from SEC Form 4 filings.
About DBV Technologies S.A.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. The company's product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. Its earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
Company website: www.dbv-technologies.com
DBVT insider activity at a glance
FilingIQ tracks 37 insider transactions for DBVT in filings since Nov 24, 2021. The most recent transaction is dated Jul 29, 2026.
Across the full history, 4 open-market purchases
and 19 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
How FilingIQ classifies each line, and the seven facts it shows on every open-market purchase and sale, are documented on the methodology page.
Latest DBVT Form 4 filings
Most recent disclosures. Sign up to filter by transaction code, insider role or dollar value.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for DBVT?
- FilingIQ tracks 37 Form 4 insider transactions for DBVT (DBV Technologies S.A.), covering filings from Nov 24, 2021 onwards. 1 of those are dated within the last 90 days.
- Are DBVT insiders net buyers or net sellers?
- Across the full Form 4 history for DBVT, 4 transactions (11%) were open-market purchases and 19 (51%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does DBVT insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ links every filing to the insider's SEC CIK, marks plan trades, tax withholding, option exercises, gifts, derivatives and amendments, and shows each open-market purchase and sale with the same fixed facts. It does not rate the stock.
- What sector is DBVT in?
- DBV Technologies S.A. (DBVT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.14B.
Methodology & sources
Every DBVT insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). How lines are classified and which facts FilingIQ adds is documented on the methodology page; the people behind it are on the team page. Not investment advice; see disclaimer.